Mei Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mei Nakamura has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Akihiko Ichida
Hepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, The University of Tokyo Hospital, Tokyo, Japan
1 shared publication- Akihiko Soyama
Department of Surgery, Division of Abdominal and Transplant/Regenerative Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
1 shared publication - Etsuro Hatano
Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
1 shared publication - Fumika Kamehama
Department of Surgery, Division of Abdominal and Transplant/Regenerative Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
1 shared publication - Fuyuki Inagaki
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan
1 shared publication - Hajime Matsushima
Department of Surgery Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Sensor-assisted firing execution (SAFE) cut: a quantitatively standardized technique for pancreatic transection in robotic distal pancreatectomy
Purpose: In robotic distal pancreatectomy (RDP), the lack of haptic feedback and delegation of stapler firing to the bedside assistant make compression quality during transection highly operator-dependent. We describe the “SAFE Cut” (Sensor-Assisted Firing Execution) technique, a quantitatively standardized protocol that converts the subjective “wait-and-fire” judgment into an objective, device-guided workflow. Methods: A smart stapler displays tissue resistance as nine stratifications across three color-coded Zones (1–1 to 3–3). A mandatory pre-firing wait (immediate to 60 s) was assigned to each segment and re-applied at every incremental firing step. We reviewed 31 consecutive patients undergoing RDP with the SAFE Cut technique, analyzing prospectively recorded Zone observations for all firing steps. Results: The protocol was completed without protocol-related conversion, repositioning, or technical failure in all 31 patients (31 of 31); in every case the stapler was operated by a bedside trainee. Median transection time was 13.3 min (8.7–23.0). CR-POPF occurred in 1 patient (3.2%), with no Grade C fistula and no 90-day mortality. Across 1,179 firing steps, Zone 1 occurred in 940 (79.7%) and Zone 2 in 239 (20.3%); Zone 3 never occurred. Because each step advances the stapler to new tissue, consecutive readings sample different segments; the step after a Zone 2 reading displayed Zone 1 in 136 of 239 events (56.9%). Conclusion: The SAFE Cut technique is feasible: the Zone-guided protocol was completed in every patient by a bedside trainee, making the previously hidden heterogeneity of tissue resistance quantifiable. This study was not designed to test fistula prevention; the CR-POPF rate was low, but a study of this size cannot establish efficacy, and whether the approach reduces fistula, and whether comparably low rates recur in other cohorts, needs prospective study.
- 14 October 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Open AccessSensor-assisted firing execution (SAFE) cut: a quantitatively standardized technique for pancreatic transection in robotic distal pancreatectomy
Purpose: In robotic distal pancreatectomy (RDP), the lack of haptic feedback and delegation of stapler firing to the bedside assistant make compression quality during transection highly operator-dependent. We describe the “SAFE Cut” (Sensor-Assisted Firing Execution) technique, a quantitatively standardized protocol that converts the subjective “wait-and-fire” judgment into an objective, device-guided workflow. Methods: A smart stapler displays tissue resistance as nine stratifications across three color-coded Zones (1–1 to 3–3). A mandatory pre-firing wait (immediate to 60 s) was assigned to each segment and re-applied at every incremental firing step. We reviewed 31 consecutive patients undergoing RDP with the SAFE Cut technique, analyzing prospectively recorded Zone observations for all firing steps. Results: The protocol was completed without protocol-related conversion, repositioning, or technical failure in all 31 patients (31 of 31); in every case the stapler was operated by a bedside trainee. Median transection time was 13.3 min (8.7–23.0). CR-POPF occurred in 1 patient (3.2%), with no Grade C fistula and no 90-day mortality. Across 1,179 firing steps, Zone 1 occurred in 940 (79.7%) and Zone 2 in 239 (20.3%); Zone 3 never occurred. Because each step advances the stapler to new tissue, consecutive readings sample different segments; the step after a Zone 2 reading displayed Zone 1 in 136 of 239 events (56.9%). Conclusion: The SAFE Cut technique is feasible: the Zone-guided protocol was completed in every patient by a bedside trainee, making the previously hidden heterogeneity of tissue resistance quantifiable. This study was not designed to test fistula prevention; the CR-POPF rate was low, but a study of this size cannot establish efficacy, and whether the approach reduces fistula, and whether comparably low rates recur in other cohorts, needs prospective study.
- Open Access
- 24 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Protocol of the STRIDE-X study: a multicenter, single-arm trial of single tremelimumab regular interval durvalumab followed by hepatectomy for initially unresectable hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and the third leading cause of cancer-related deaths. Systemic therapies such as lenvatinib or the combination of atezolizumab and bevacizumab have recently emerged as first-line therapies for advanced HCC. The introduction of tremelimumab with durvalumab (STRIDE regimen) has shown potential in improving overall survival (OS) in unresectable cases, making these patients candidates for surgical intervention post-treatment. Methods: The STRIDE-X study is a prospective, multicenter, single-arm trial aimed at evaluating the efficacy of single-dose tremelimumab combined with durvalumab, followed by hepatectomy, in patients with initially unresectable HCC. This non-randomized, open-label study will enroll subjects based on specific inclusion criteria. Eligible patients will undergo initial intravenous doses of tremelimumab and durvalumab, followed by an assessment of resectability via imaging at 8 and 16 weeks. If tumors become resectable, surgery will be scheduled 3–8 weeks after the last treatment dose. The primary endpoint is the incidence of postoperative complications of Clavien–Dindo grade III or higher following hepatectomy performed after STRIDE therapy. Secondary endpoints include resection rate, on-protocol resection rate, curative resection rate, post-hepatectomy liver failure, progression-free survival (PFS), OS, overall response rate, and ICG retention rate following STRIDE therapy. Safety and quality of life during the treatment course will also be assessed. Exploratory endpoints include analyses of plasma PD-L1, PD-1, CTLA-4, cytokines, circulating tumor DNA, and the immunological evaluation of resected surgical specimens. Discussion: This study aims to elucidate the safety of conversion surgery with the STRIDE regimen for initially unresectable HCC. In addition, efficacy (PFS and OS), the conversion rate during the treatment course, and analyses of relevant biomarkers will also be assessed.
- 24 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Open AccessProtocol of the STRIDE-X study: a multicenter, single-arm trial of single tremelimumab regular interval durvalumab followed by hepatectomy for initially unresectable hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and the third leading cause of cancer-related deaths. Systemic therapies such as lenvatinib or the combination of atezolizumab and bevacizumab have recently emerged as first-line therapies for advanced HCC. The introduction of tremelimumab with durvalumab (STRIDE regimen) has shown potential in improving overall survival (OS) in unresectable cases, making these patients candidates for surgical intervention post-treatment. Methods: The STRIDE-X study is a prospective, multicenter, single-arm trial aimed at evaluating the efficacy of single-dose tremelimumab combined with durvalumab, followed by hepatectomy, in patients with initially unresectable HCC. This non-randomized, open-label study will enroll subjects based on specific inclusion criteria. Eligible patients will undergo initial intravenous doses of tremelimumab and durvalumab, followed by an assessment of resectability via imaging at 8 and 16 weeks. If tumors become resectable, surgery will be scheduled 3–8 weeks after the last treatment dose. The primary endpoint is the incidence of postoperative complications of Clavien–Dindo grade III or higher following hepatectomy performed after STRIDE therapy. Secondary endpoints include resection rate, on-protocol resection rate, curative resection rate, post-hepatectomy liver failure, progression-free survival (PFS), OS, overall response rate, and ICG retention rate following STRIDE therapy. Safety and quality of life during the treatment course will also be assessed. Exploratory endpoints include analyses of plasma PD-L1, PD-1, CTLA-4, cytokines, circulating tumor DNA, and the immunological evaluation of resected surgical specimens. Discussion: This study aims to elucidate the safety of conversion surgery with the STRIDE regimen for initially unresectable HCC. In addition, efficacy (PFS and OS), the conversion rate during the treatment course, and analyses of relevant biomarkers will also be assessed.